Anthony M Sammel1,2,3, Susan Smith4, Katherine Nguyen1, Rodger Laurent1,2, Janice Brewer1, Nathan Hall1, Christopher B Little2,4. 1. Departments of Rheumatology and Anatomical Pathology, Royal North Shore Hospital, St Leonards, Sydney, New South Wales, Australia. 2. Northern Clinical School, University of Sydney, St Leonards, Sydney, New South Wales, Australia. 3. Department of Rheumatology, Prince of Wales Hospital, Randwick, Sydney, New South Wales, Australia. 4. Raymond Purves Bone and Joint Research Laboratories, Kolling Institute, St Leonards, Sydney, New South Wales, Australia.
Abstract
OBJECTIVES: There is uncertainty if varicella zoster virus (VZV) triggers GCA. This is based on discordant reports of VZV detection in GCA temporal artery biopsies. We conducted a multimodal evaluation for VZV in the inception Giant Cell Arteritis and PET Scan (GAPS) cohort. METHODS: Consecutive patients who underwent temporal artery biopsy for suspected GCA were clinically reviewed for active and past VZV infection and followed for 6 months. Serum was tested for VZV IgM and IgG. Temporal artery biopsy (TAB) sections were stained for VZV antigen using the VZV Mouse Cocktail Antibody (Cell Marque, Rocklin, CA, USA). A selection of GCA and control tissues were stained with the VZV gE antibody (Santa Cruz Biotechnology, Dallas, TX, USA), which was used in previous studies. RESULTS: A total of 58 patients met inclusion criteria, 12 (21%) had biopsy-positive GCA and 20 had clinically positive GCA. None had herpes zoster at enrolment and only one patient developed a VZV clinical syndrome (zoster ophthalmicus) on follow-up. There was no difference in VZV exposure between GCA and non-GCA patients. None of the 53 patients who had VZV serology collected had positive VZV IgM antibodies. VZV antigen was not convincingly demonstrated in any of the TAB specimens; 57 TABs stained negative and 1 stained equivocally positive. The Santa Cruz Biotechnology VZV antibody exhibited positive staining in a range of negative control tissues, questioning its specificity for VZV antigen. CONCLUSION: The absence of active infection markers argues against VZV reactivation being the trigger for GCA. Non-specific immunohistochemistry staining may account for positive findings in previous studies.
OBJECTIVES: There is uncertainty if varicella zoster virus (VZV) triggers GCA. This is based on discordant reports of VZV detection in GCA temporal artery biopsies. We conducted a multimodal evaluation for VZV in the inception Giant Cell Arteritis and PET Scan (GAPS) cohort. METHODS: Consecutive patients who underwent temporal artery biopsy for suspected GCA were clinically reviewed for active and past VZVinfection and followed for 6 months. Serum was tested for VZV IgM and IgG. Temporal artery biopsy (TAB) sections were stained for VZV antigen using the VZVMouse Cocktail Antibody (Cell Marque, Rocklin, CA, USA). A selection of GCA and control tissues were stained with the VZV gE antibody (Santa Cruz Biotechnology, Dallas, TX, USA), which was used in previous studies. RESULTS: A total of 58 patients met inclusion criteria, 12 (21%) had biopsy-positive GCA and 20 had clinically positive GCA. None had herpes zoster at enrolment and only one patient developed a VZV clinical syndrome (zoster ophthalmicus) on follow-up. There was no difference in VZV exposure between GCA and non-GCA patients. None of the 53 patients who had VZV serology collected had positive VZV IgM antibodies. VZV antigen was not convincingly demonstrated in any of the TAB specimens; 57 TABs stained negative and 1 stained equivocally positive. The Santa Cruz Biotechnology VZV antibody exhibited positive staining in a range of negative control tissues, questioning its specificity for VZV antigen. CONCLUSION: The absence of active infection markers argues against VZV reactivation being the trigger for GCA. Non-specific immunohistochemistry staining may account for positive findings in previous studies.
Authors: Robert M Verdijk; Werner J D Ouwendijk; Robert W A M Kuijpers; Georges M G M Verjans Journal: J Infect Dis Date: 2021-01-04 Impact factor: 5.226
Authors: Andrew N Bubak; Teresa Mescher; Michael Mariani; Seth E Frietze; James E Hassell; Christy S Niemeyer; Christina N Como; Anna M Burnet; Prem S Subramanian; Randall J Cohrs; Ravi Mahalingam; Maria A Nagel Journal: Neurol Neuroimmunol Neuroinflamm Date: 2021-09-07
Authors: Kornelis S M van der Geest; Maria Sandovici; Elisabeth Brouwer; Sarah L Mackie Journal: JAMA Intern Med Date: 2020-10-01 Impact factor: 21.873